RT Journal Article
SR Electronic
T1 Changes in Apolipoprotein A1 and B, Glucose Metabolism, and Skeletal Muscle Mass in Peripheral Artery Disease after Endovascular Treatment: A Pilot Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.01.22273293
DO 10.1101/2022.04.01.22273293
A1 Ikeda, Takeshi
A1 Komiyama, Hidenori
A1 Miyakuni, Tomoyo
A1 Takano, Masamichi
A1 Matsushita, Masato
A1 Kobayashi, Nobuaki
A1 Asai, Kuniya
A1 Shimizu, Wataru
A1 Miyauchi, Yasushi
YR 2022
UL http://medrxiv.org/content/early/2022/04/01/2022.04.01.22273293.abstract
AB Peripheral artery disease impairs walking and physical activity, resulting in further loss of skeletal muscle. However, peripheral artery disease can be treated with endovascular treatment. The thigh muscle has been shown to correlate with systemic skeletal muscle volume. We assessed the changes in the metabolism of apolipoproteins A1 and B, blood glucose, and thigh muscle mass after endovascular treatment in above-the-knee peripheral artery disease where vessels supply the thigh muscle. Mid-thigh muscle volume was measured with computed tomography before and at 6 months after endovascular treatment. Apolipoproteins A1 and B, fasting blood glucose, post-load (75 g oral glucose tolerance test) 2 h-blood glucose, and glycated hemoglobin A1c (HbA1c) levels were measured concomitantly. The relationships between changes in apolipoproteins A1, apolipoproteins B, blood glucose, post-oral glucose tolerance test 2 h-blood glucose, Rutherford classification, and gain or loss of thigh muscle were investigated. Thigh muscle mass did not correlate with changes in apolipoproteins A1, B, fasting glucose, post-oral glucose tolerance test 2 h-blood glucose, HbA1c, and Rutherford classification. Among patients with muscle gain post-endovascular treatment, apolipoproteins A1 increased significantly, while apolipoproteins B levels were similar. Post-oral glucose tolerance test 2 h-blood glucose levels decreased. Preferable metabolic changes were observed in patients with skeletal muscle gain contrasted with muscle loss.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialIRB number: 504Funding Statement6446Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:institutional review board of the Nippon Medical School Chiba Hokusoh Hospital approved this study (IRB number: 504)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableData used in this paper cannot be shared publicly because of its confidential nature and to prevent deductive disclosure of the identity of the study participants.